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a b s t r a c t
Galectin-3 has previously been found to be required by the parvovirus minute virus of mice prototype
strain (MVMp) for infection of mouse ﬁbroblast cells. Since MVMp is an oncotropic virus, and galectin-3
is a multifunctional protein implicated in cancer metastasis, we hypothesized that galectin-3 and Mgat5,
the Golgi enzyme that synthesizes high-afﬁnity glycan ligands of galectin-3, might play a role in MVMp
infection. Using siRNA-mediated knockdown of galectin-3 in mouse cells transformed with polyoma-
virus middle T antigen and Mgat5/ mouse mammary tumor cells, we found that galectin-3 and Mgat5
are both necessary for efﬁcient MVMp cell entry and infection, but not for cell binding. Moreover, we
found that human cancer cells expressing higher levels of galectin-3 were more efﬁciently infected with
MVMp than cell lines expressing lower galectin-3 levels. We conclude that galectin-3 and Mgat5 are
involved in MVMp infection, and propose that galectin-3 is a determinant of MVMp oncotropism.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Galectin-3 (Gal-3) is a member of the β-galactoside-binding
lectin family of proteins, which bind to carbohydrates (reviewed
by Boscher and Nabi, 2013; Vasta, 2012). Speciﬁcally, Gal-3 binds
to the β1,6 branched N-glycans of glycoproteins on the cell surface,
which are the products of the Golgi enzyme β1,6-acetylglucosa-
minyltransferase 5 (Mgat5) (reviewed by Boscher et al., 2011). On
the cell surface, Gal-3 interacts with several ligands, including
integrins and epidermal-growth factor receptor (EGFR) (reviewed
by Boscher et al., 2011). Therefore, it has been proposed that Gal-3
modulates the clustering and signaling activity of receptors on the
plasma membrane (Boscher et al., 2011; Goetz, 2009). Similarly,
through its interactions with Mgat5 modiﬁed N-glycans of various
cell surface receptors and proteins, Gal-3 modulates several
cellular functions, such as signal transduction on the cell surface
and cell adhesion, motility, growth, and differentiation (Dennis et al.,
2009b). Since some of these functions are altered in tumorigenic
cells, Gal-3 regulates many physiological and pathological cellular
processes. However, a role for Gal-3 in viral infection has only
recently been discovered. In a proteomic study, Gal-3 and its binding
protein, Gal-3-binding protein (Gal-3-BP), were identiﬁed as cellular
partners of the parvovirus minute virus of mice prototype strain
(MVMp) (Garcin et al., 2013). In addition, a screen for serum proteins
that interact with different adeno-associated virus (AAV; another
parvovirus) types identiﬁed Gal-3-BP as a binding partner of AAV
(Denard et al., 2012). It was subsequently shown that Gal-3 is
required for efﬁcient MVMp cellular uptake and infection, but not
for viral binding to the plasma membrane (Garcin et al., 2013), and
that Gal-3-BP reduces AAV-6 transduction (Denard et al., 2012). In
addition to these parvoviruses, it has also been reported that herpes
simplex virus type 1 (HSV-1) uses extracellular Gal-3 for cell entry
(Woodward et al., 2013).
MVM is a small (26 nm in diameter), non-enveloped virus with
a single-stranded DNA genome that belongs to the Parvoviridae
family (Cotmore et al., 2014). The MVM genome is protected by a
capsid assembled from 60 copies of two size variants of the capsid
proteins VP1 and VP2, which are identical, except for the unique
N-terminal sequence (140 amino acids) of VP1 (Tattersall et al.,
1977). Several strains of MVM exist, but the best characterized
strains are the prototype MVMp that infects cells of ﬁbroblast
origin and the immunosuppressive strain MVMi that infects T
lymphocytes (Tattersall and Bratton, 1983). This MVM tropism is
controlled predominantly by the capsid protein VP2, with only
two amino acid substitutions on this protein making the virus
ﬁbrotropic or lymphotropic (Ball-Goodrich and Tattersall, 1992).
Several parvoviruses attach to their target cells via binding of
capsid proteins to glycan receptors (reviewed by Huang et al., 2014).
For example, human parvovirus B19 uses gangliosides (Cooling et al.,
1995), AAV2 uses heparan sulfate proteoglycan (Kern et al., 2003), and
rat H-1 parvovirus, porcine parvovirus, and MVM use sialic acid
(Allaume et al., 2012; Boisvert et al., 2010; Nam et al., 2006). A recent
sialylated glycan microarray revealed that MVM binds to diverse
sialylated derivatives, but there was different recognition between
MVMp and MVMi (Halder et al., 2014). For example, MVMp, but not
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MVMi, binds to 9-O-acetylated and 9-O-lactoylated sialic acid deriva-
tives (Halder et al., 2014). Despite this difference, MVM attachment to
sialic acid induces virion internalization by clathrin-dependent endo-
cytosis (Linser et al., 1977, 1979; Vihinen-Ranta and Parrish, 2006)
(reviewed by Vihinen-Ranta and Parrish, 2006), and possibly other
endocytic pathways as has been recently shown for other parvoviruses
(Bantel-Schaal et al., 2009; Boisvert et al., 2010; Nonnenmacher and
Weber, 2011). Following endocytosis, MVM escapes from endocytic
compartments into the cytosol by means of the enzymatic action of a
phospholipase A2 (PLA2) domain in the unique region of VP1 (Farr
et al., 2005). The virions that escape the endosomes then enter the
nucleus where they wait for the host cell to transition into the S-phase,
to initiate viral DNA replication (Cotmore and Tattersall, 2006).
MVMp and other rodent parvoviruses have several properties that
make them good candidates for development as cancer therapies
(reviewed by Nuesch et al., 2012; Rommelaere et al., 2010). In fact,
there is an ongoing clinical trial using the rat parvovirus H-1 in
patients with recurrent glioblastoma (Geletneky et al., 2012). For
MVMp, it is well established that in vitro this virus preferentially
infects human tumor cells that are stably transformed or in which
transformation has been induced (Legrand et al., 1993; Mousset et al.,
1986; Wollmann et al., 2005; Zeicher et al., 2003). The molecular bases
of this MVMp oncotropism are not completely understood. Never-
theless, several parameters have been associated with MVMp onco-
tropism. These include the S-phase dependence of viral replication
(Burnett and Tattersall, 2003; Deleu et al., 1999), the MVMp sensitivity
to the antiviral response (Grekova et al., 2010; Mattei et al., 2013),
Raf-1-dependent phosphorylation of the viral structural protein VP2
(Riolobos et al., 2010), post-translational modiﬁcations of the viral
non-structural protein NS1 (Nuesch et al., 2003), and the process of
epithelial–mesenchymal transition (Garcin and Pante, 2014).
Since Gal-3 has been implicated in cancer progression (Miranda
et al., 2009; Mourad-Zeidan et al., 2008; Takenaka et al., 2004; Wang
et al., 2013, 2009) and is considered as a potential marker for
aggressive tumor cells (Chiu et al., 2010; Shankar et al., 2012), we
hypothesized that Gal-3 and Mgat5 might be involved in MVMp
infection. To test this hypothesis, we characterized the role of Gal-3
and Mgat5 in the infectious cycle of MVMp. Using small interfering
ribonucleic acid (siRNA) to silence Gal-3 expression and cells derived
from Mgat5 knockout mice (Mgat5/ cells Granovsky et al., 2000),
we found that Gal-3 and Mgat5 are required for efﬁcient MVMp
uptake and infection. In a screen of human cancer cells from various
tissues, we also found a correlation between the Gal-3 expression
proﬁle of these cells and their susceptibility to MVMp infection,
indicating that Gal-3 could be involved in MVMp oncotropism. Taken
together, our results show that Gal-3 and Mgat5 are necessary for
MVMp uptake and infection, and we propose Gal-3 as a potential
regulator of MVMp oncotropism.
Results
Galectin-3 knockdown hampers MVMp infection in PyMT cells
It has been reported that Gal-3 is involved in MVMp uptake and
infection of LA9 mouse ﬁbroblast cells (Garcin et al., 2013). Therefore,
we ﬁrst conﬁrmed this observation in a different cellular model
derived from PyMT-transformed mouse mammary epithelial cells
(Granovsky et al., 2000). These cells have been used to study the
various cellular functions of Gal-3, such as its role in cell migration
(Goetz et al., 2008). We ﬁrst performed siRNA-mediated Gal-3
knockdown (KD) experiments in PyMT cells, and conﬁrmed Gal-3
KD by immunoﬂuorescence (IF) microscopy and Western blot
analysis, which showed that Gal-3 levels were signiﬁcantly reduced
at 48 h post-transfection (Fig. 1A and B). These cells were then
infected with MVMp at an MOI of 4 for 24 h at 37 1C, and then
prepared for MVMp infection analysis by IF microscopy. The viral
protein NS1 (which is used for measuring MVMp replication and
infection since it is the ﬁrst viral protein that is expressed upon
successful MVM infection and it initiates viral DNA replication Doerig
et al., 1990, 1988) and Gal-3 were detected using speciﬁc antibodies.
As shown in Fig. 1C and D, the percentage of NS1-expressing cells
was lower in cells treated with Gal-3 siRNA than in those treated
with Lipofectamine or a non-targeting control siRNA. These results
indicate that Gal-3 is required for efﬁcient MVMp infection of PyMT
cells, in agreement with previously published data in LA9 cells
(Garcin et al., 2013).
Galectin-3 knockdown reduces MVMp uptake by PyMT cells
Next, we analyzed the effect of Gal-3 KD on MVMp cell entry by IF
microscopy. PyMT cells were transfected with Gal-3 siRNA, a control
siRNA, or Lipofectamine, and subsequently infected with MVMp at an
MOI of 4 for 2 h at 37 1C in the presence of baﬁlomycin A1 (bafA1).
BafA1 inhibits the vacuolar Hþ-ATPase in the endosomal membrane
that is responsible for acidiﬁcation (Bayer et al., 1998); thus, MVMp
arrests in early endosomes, which allows for better observation of the
virions that enter the cells. As shown in Fig. 2, MVMp uptake was
signiﬁcantly lower in PyMT cells treated with Gal-3 siRNA than in
control cells. This indicates that, similar to the results observed in LA9
cells (Garcin et al., 2013), Gal-3 promotes MVMp uptake in PyMTcells.
MVMp does not infect Mgat5 / cells
It is well known that Mgat5 overexpression in cancer cells
promotes tumor progression and invasion in a Gal-3-dependent
manner (reviewed by Dennis et al., 2009b). Hence, we next tested
the possible role of Mgat5 in MVMp infection using PyMT mouse
epithelial mammary tumor cells derived fromMgat5 knockout mice
(Mgat5/ cells, Granovsky et al., 2000). Total lysates of LA9, PyMT,
Mgat5/ , and Mgat5-rescued (Mgat5 / cells stably transfected
with a retroviral Mgat5 expressing vector, Partridge et al., 2004)
cells were blotted and ﬁrst probed for Mgat5-modiﬁed N-glycosyla-
tion using Phaseolus vulgaris lectin-coupled horseradish peroxidase
(L-PHA-HRP) to verify that the Mgat5 / cells lack these glycosyla-
tions. As shown in Fig. S1, in contrast to LA9 and PyMT cells,
Mgat5/ cells were indeed deﬁcient in Mgat5-modiﬁed N-glycans.
Moreover, Mgat5-rescued cells displayed much higher levels of
Mgat5 expression than LA9 and PyMT cells.
These cells were then infected with MVMp at an MOI of 8 for
24 h at 37 1C and prepared for IF microscopy to detect both the
viral NS1 protein and the newly produced viral particles that
should have already been generated at 24 h post-infection. MVMp
capsids and NS1 protein were detected with speciﬁc antibodies. As
shown in Fig. 3, approximately 80% of the LA9 and PyMT cells were
positive for NS1 and MVMp progeny. Strikingly, Mgat5 / cells
showed neither NS1 expression nor progeny virion production,
indicating that these cells are resistant to MVMp infection. This
phenotype was reversed in Mgat5-rescued cells, which were as
permissive to MVMp infection as the wild-type PyMT cells (Fig. 3).
These ﬁndings were validated by measuring NS1 expression levels
in cell lysates from all four cell lines after 24 h of infection with
MVMp at an MOI of 8. As shown in Fig. 4A, no NS1 was detected in
Mgat5 / cells, whereas LA9, PyMT, and Mgat5-rescued cells
showed comparable amounts of NS1.
To further test the resistance of Mgat5 / cells to MVMp infection,
we performed plaque assays with MVMp and all four cell lines. In this
experiment, the cells were infected with various concentrations of
virus for 4 days, and then, virus-induced cell lysis was observed as
the formation of plaques. As shown in Fig. 4B, Mgat5 / cells were
resistant to MVMp infection even at higher viral concentrations, while
all the other cell types showed plaques even at a virus dilution
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of 1104. To ensure that the lack of MVMp infection observed in
Mgat5 / cells was not due to reduced proliferation of these cells
(since MVMp requires cells in S-phase to establish infection), we
performed cell proliferation assays with LA9, PyMT, Mgta5 / , and
Mgat5-rescued cells. The results of these assays showed that the cell
division rate of Mgat5/ cells was much higher than that of LA9 and
PyMT cells, and that Mgat5-rescued cells proliferated more slowly
than the other cell lines (Fig. S2). Hence, the inability of MVMp to
infect the Mgta5 / cells (Figs. 3 and 4) was not due to a reduction in
cell division rate.
MVMp cellular uptake, but not cell surface binding, is reduced
in Mgat5 / cells
The previous results indicated that the inhibition of MVMp
infection observed in Mgat5/ cells occurs upstream of the replica-
tion step in the viral infection cycle. Therefore, we hypothesized that
an alteration in MVMp uptake could be the cause of this inhibition. To
test this hypothesis, PyMT, Mgat5 / , and Mgat5-rescued cells were
infected with MVMp at an MOI of 8 for 4 h at 37 1C in the presence of
bafA1, and then the cells were prepared for IF microscopy. As shown
in Fig. 5, MVMp uptake was lower in Mgat5/ cells than in PyMT
and Mgat5-rescued cells. In order to verify that the limited MVMp
uptake in Magt5/ cells was not a consequence of reduced virus
attachment to the plasmamembrane, we analyzedMVMp cell surface
binding in PyMT, Mgat5 / , and Mgat5-rescued cells by ﬂuorescence
activated cell sorting (FACS). For this experiment, cells were incubated
with MVMp at an MOI of 8 for 30 min at 4 1C, rinsed, ﬁxed, and
prepared for FACS analysis without permeabilization (thus only
virions at the cell surface are detected). As shown in Fig. 6, this
experiment showed that MVMp binding to the cell surface was not
reduced in Mgat5/ cells when compared to PyMT and Mgat5-
rescued cells, as the ﬂuorescence intensity of cell-bound MVMp
(Fig. 6, red binding curve) was comparable in all three cell lines.
Hence, the reduced MVMp uptake in Mgat5 / cells (Fig. 5) is not
due to reduced MVMp binding to the plasma membrane.
Gal-3 expression is correlated with MVMp infection
Since Gal-3 is often associated with cancer progression (Miranda
et al., 2009; Mourad-Zeidan et al., 2008; Takenaka et al., 2004; Wang
et al., 2013, 2009), and is also considered a reliable marker for some
invasive tumors (Chiu et al., 2010; Shankar et al., 2012), we next asked
whether its expression levels in human cancer cells were correlated
with MVMp infection. For this purpose, we assessed the MVMp
infection susceptibility of several human cancer cell lines originating
from various tissues, which are well characterized with regard to their
Gal-3 expression levels. For this screening experiment, we chose
thyroid (T238 and TPC1), breast (MCF7 and MDA-231), and prostate
(LnCap and PC3) cancer cell lines with low or high Gal-3 expression
proﬁles. Gal-3 cellular levels were ﬁrst veriﬁed by Western blotting
(Fig. 7). In agreement with the literature, T238, MCF7, and LnCap cells
displayed lower Gal-3 expression than TPC1, MDA-231, and PC3 cells,
respectively (Pacis et al., 2000; Sathisha et al., 2007; Shankar et al.,
2012). These cells were then infected with MVMp at an MOI of 2 for
24 h at 37 1C and prepared for IF microscopy. NS1 protein was
detected using a speciﬁc antibody. As shown in Fig. 8, the cell lines
with higher Gal-3 expression, including TPC1, MDA-231, and PC3,
Fig. 1. MVMp infectivity is reduced in Gal-3 siRNA knockdown PyMT cells. (A) PyMT cells were either mock transfected with Lipofectamine, or transfected with siRNA
targeting Gal-3 or control siRNA and prepared for IF microscopy 48 h post-transfection. Gal-3 (green) was detected using a speciﬁc antibody and ﬂuorescently-labeled
phalloidin was used for detection of actin ﬁlaments (white). (B) Western blot analysis of PyMT cell lysates after Gal-3 siRNA KD as described in A. (C) PyMT cells were siRNA
KD for Gal-3 as described in A, infected with MVMp at an MOI of 4 for 24 h at 37 1C, and prepared for IF microscopy using antibodies against NS1 (magenta) and Gal-3
(green). DAPI was used for detection of the nucleus (blue). (D) Quantiﬁcation of NS1 positive cells as observed by IF microscopy from three independent experiments. Bar
graphs show the mean7standard error of the mean (n¼600, ** po0.01).
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were more efﬁciently infected with MVMp than the cell lines with
lower Gal-3 levels. Strikingly, the TPC1 cells were even more
susceptible to MVMp infection than LA9 cells. This indicates that
Gal-3 expression may be another determinant of MVMp oncotropism.
To ensure that the limited MVMp infection observed in cells
with low Gal-3 expression was not due to reduced cell prolifera-
tion of these cells (since MVMp requires S-phase cells to establish
infection), we performed cell proliferation assays with all the cells
used in the screening. The results of these assays revealed that the
breast and prostate cancer cell lines used here proliferate more
slowly than LA9 cells (Fig. S3). In contrast, the thyroid cancer cells
showed the greatest cell proliferation rates, especially the TPC1
cells. Thus, it appears that the reduced MVMp infection observed
in cells with low Gal-3 expression (Fig. 8) is not the result of
limited cell division, even though the greater MVMp infection
observed in TPC1 cells may be partially related to the high
proliferation rate of these cells.
Discussion
In this work, we report our ﬁnding that Gal-3 and Mgat5, two
important regulators of cancer progression, are crucial for MVMp
infection. We show that Gal-3 is necessary for efﬁcient MVMp uptake
and infection in PyMT transformed mammary carcinoma cells, and
that Mgat5 / tumor cells cannot be infected with MVMp. Moreover,
we found a correlation between the level of Gal-3 expression and
susceptibility to MVMp infection in several human cancer cell lines.
We ﬁrst showed that siRNA-mediated Gal-3 KD hampered
MVMp cellular uptake and infection in PyMT cells, in agreement
with a previous report in LA9 cells (Garcin et al., 2013). It has been
well established that Gal-3 pentamers can assemble into a lattice
upon binding to Mgat5-modiﬁed N-glycans exposed by various
cell surface receptors (Boscher et al., 2011; Brewer et al., 2002;
Lajoie et al., 2009). This property allows Gal-3 to modulate the
clustering and endocytosis of these receptors at the cell surface.
Hence, based on our observation that Gal-3 plays a role in MVMp
infection (Figs. 1 and 2), and given the interplay between Gal-3
and Mgat5, we expected that MVMp infection would be affected
by the absence of Mgat5. Indeed, Mgat5 / cells were extremely
resistant to MVMp infection (Figs. 3 and 4). In comparison, Gal-3
KD in PyMT cells only resulted in a partial inhibition of MVMp
infection at an MOI of 4 (Fig. 1), whereas Mgat5/ cells were not
infected with MVMp even at an MOI of 8 and at up to 4 days post-
infection (Fig. 4B). Moreover, Mgat5-rescued cells were infected
with MVMp as efﬁciently as PyMT cells (Fig. 3), indicating that
MVMp requires Mgat5 expression to establish a productive infec-
tion. Notably, the proliferation rate of Mgat5/ cells was much
higher than that of PyMT cells, which divided more rapidly than
LA9 and Mgat5-rescued cells (Fig. S2). Hence, Mgat5 does not have
a negative effect on cell cycling. Moreover, since MVMp requires
the cells to enter S-phase for replication (Burnett and Tattersall,
2003; Deleu et al., 1999), Mgat5 must be acting in a step of the
MVM life cycle before viral DNA replication. We also found that
MVMp infection was strongly prevented in Mgat5/ cells, even
though MVMp uptake was only partially inhibited in these cells.
This indicates that an additional function of Mgat5 (other than its
role in MVMp uptake) is required for the MVMp infection cycle.
The binding of MVMp to the plasma membrane was not
affected in Mgat5 / cells (Fig. 6), which was also observed in
the Gal-3 KD LA9 cells (Garcin et al., 2013). This was unexpected,
as our ﬁrst hypothesis was that Mgat5 might contribute to the
creation of additional plasma membrane receptors for MVMp, as it
does for Gal-3 (reviewed by Dennis et al., 2009a). Hence, our
results indicate that Gal-3 is involved in the endocytosis of MVMp
rather than in the virus binding to the cell surface. This is further
supported by studies showing that the higher afﬁnity ligands are
different for MVMp (sialic acids, Nam et al., 2006) and Gal-3 (β1,6
branched N-glycans, reviewed by Boscher et al., 2011). The role of
Gal-3 in endocytosis has not yet been well established, although
earlier studies reported a role for Gal-3 in the endocytosis of
integrins (Furtak et al., 2001) and cytokine receptors (Partridge
et al., 2004). More recently, Gal-3 was shown to modify the
diffusion of glycosphingolipid-bound cholera toxin B subunit in
adherent junctions and to trigger glycosphingolipid-dependent
formation of clathrin-independent carriers, with the latter also
requiring N-glycans (Boscher et al., 2012; Lakshminarayan et al.,
2014). The authors proposed that Gal-3 is involved in the plasma
membrane bending for the formation of clathrin-independent
carriers pits (Lakshminarayan et al., 2014). Hence, we envision
that the role of Gal-3 in MVMp uptake might be to induce bending
of the plasma membrane for subsequent viral endocytosis in an
Mgat5-dependent manner. It remains to be determined whether such
a model is valid for MVMp, which enters its target cells via clathrin-
dependent endocytosis (reviewed by Vihinen-Ranta and Parrish,
Fig. 2. MVMp cellular uptake is reduced in Gal-3 siRNA knockdown PyMT cells.
(A) PyMT cells were either mock transfected or transfected with siRNA targeting
Gal-3 or control siRNA, pre-incubated with medium containing bafA1 for 1 h (to
inhibit endosomal acidiﬁcation and MVMp escape from endosomes) and then
incubated with MVMp at an MOI of 4 for 15 min at 4 1C in the presence of bafA1.
After this time the virus-containing medium was removed, replaced with medium
containing bafA1, and viral uptake was allowed for 2 h at 37 1C. Cells were then
prepared for IF microscopy using anti-MVMp (red) and anti-Gal-3 (green) anti-
bodies and DAPI for detection of the nucleus (blue). (B) Quantiﬁcation of MVMp
ﬂuorescence intensity signal as observed by IF microscopy from three independent
experiments performed as described in A. Bar graphs show the mean7standard
error of the mean (n¼500, * po0.05).
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2006). However, since recent studies have shown that parvoviruses
can use several endocytic pathways, including clathrin-independent
endocytosis, caveolae-dependent endocytosis, and macropinocytosis
(Bantel-Schaal et al., 2009; Boisvert et al., 2010; Nonnenmacher and
Weber, 2011), it is possible that MVMp uses clathrin-independent
carriers for cell entry.
An alternative model for the role of Gal-3 in MVMp endocytosis
is that the crosslinking of Mgat5-modiﬁed glycoproteins at the cell
surface by Gal-3 induces Mgat5-dependent cell signaling, which
then allows for the formation of MVMp-containing pits. In this
case, the MVMp receptor would simply allow the virus to reach
the domains of the plasma membrane where the signaling activity
(Gal-3- and Mgat5-dependent) of its co-receptor would promote
viral endocytosis. This is somewhat true for the human parvovirus
B19, which requires activation of its co-receptor, α5β1-integrin, to
enter and infect adherent K562 cells (Weigel-Kelley et al., 2003). In
addition, our previous ﬁnding that mesenchymal cell migration is
a player in MVMp infection (Garcin and Pante, 2014), together
with the data presented in the present paper, may indicate that
the well-known ability of Gal-3 to directly promote cancer cell
migration and invasion is required for MVMp infection.
Gal-1 has been implicated in the infection of other viruses such as
HIV-1, inﬂuenza A, and Nipah virus (Garner et al., 2010; St-Pierre et al.,
2012; Yang et al., 2011). For HIV-1, soluble Gal-1 was shown to
promote HIV-1 binding to its target cells (CD4þ lymphocytes) via
direct interaction of Gal-1 with both viral gp120 and the host CD4
receptor (St-Pierre et al., 2012). In contrast, Gal-1 displayed anti-viral
activities against inﬂuenza A and Nipah virus infection by direct
binding to the viral envelope glycoproteins involved in viral cell entry
(Garner et al., 2010; Yang et al., 2011). Based on our results, Gal-3 is
necessary for efﬁcient MVMp infection, but is not required for the
binding of MVMp to the plasma membrane of LA9 cells (Garcin et al.,
2013). Hence, it appears as though the mechanism by which Gal-3
regulates MVMp early infection is different from the one by which
Gal-1 regulates HIV-1 infection, most likely because unlike HIV-1,
MVMp is a non-enveloped virus.
Gal-3 is considered to be a potential marker for aggressive
tumors, including thyroid, prostate, and breast cancers (Chiu et al.,
Fig. 3. MVMp infectivity is abolished in Mgat5 / cells as shown by IF microscopy. (A) LA9, PyMT, Mgat5/ , and Mgat5-rescued (Mgat5-R) cells were infected with
MVMp at an MOI of 8 for 24 h at 37 1C and prepared for IF microscopy analysis. MVMp (red) and the NS1 protein (pseudocolored in magenta) were detected using speciﬁc
antibodies, and DAPI (blue) was used to observe the nucleus. (B) Quantiﬁcation of the percentage of cells positive for NS1 expression or MVMp progeny from three
independent experiments performed as described in A. Bar graphs show the mean7standard error of the mean (n¼1000, * po0.05; ** po0.01). ns: not signiﬁcant.
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2010; Shankar et al., 2012). We now show that Mgat5 and Gal-3
expression are critical determinants of MVMp infection (Figs. 1–4).
Therefore, we suspected that there could be a correlation between
Gal-3 expression and the ability of MVMp to preferentially infect
cancer cells. Indeed, this is what we observed in our small screen
for MVMp permissivity in cancer cells originating from various
tissues. In human cancer cells, as shown in Fig. 8, MVMp was barely
able to infect any of the poorly invasive cancer cells with low Gal-3
levels, whereas MVMp efﬁciently infect the cells with higher Gal-3
expression. This suggests that similar to Gal-3 (Chiu et al., 2010;
Shankar et al., 2012), MVMp could be used as a marker for
aggressive tumors. More importantly, targeting of Gal-3/Magt5-
positive tumor cells by MVMp could enable tumor destruction, as
virus replication can lead to cell lysis, with considerable localized
ampliﬁcation of oncolytic material.
In conclusion, the results presented in this paper identify Gal-3
and the Golgi enzyme Mgat5 as determinants of MVMp infection.
Moreover, the correlation between Gal-3 expression and MVMp
infection in various human cancer cell lines suggests that Gal-3 is
one more player in MVMp oncotropism.
Materials and methods
Cell culture and virus production
Cells used in this study were: LA9 mouse ﬁbroblast cells, mouse
epithelial mammary tumor cells transformed with polyomavirus
middle T antigen (PyMT cells Granovsky et al., 2000), PyMT cells
derived from Mgat5 knockout mice (Mgat5/ cells Granovsky et al.,
2000), Mgat5/ cells stably transfected with a retroviral Mgat5
expressing vector (Mgat5-rescued cells Partridge et al., 2004), and
the human thyroid (Shankar et al., 2012), prostate (Pacis et al., 2000),
and breast (Sathisha et al., 2007) cancer cell lines. All cells were
maintained at 5% CO2 and 37 1C in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
1% glutamine and penicillin-streptomycin. MVMp was produced and
puriﬁed based on the procedures described by Tattersall et al. (1976)
and Williams et al. (2004) with an extended step of dialysis to
completely remove cesium chloride. The yield was assessed by
plaque assay to be 2.1109 plaque-forming units per milliliter
(pfu/ml), and a particle to infectivity ratio of about 2500 particles/pfu.
Antibodies and reagents
Mouse antibody MAb B7 against assembled capsids (Kaufmann
et al., 2007) and mouse antibody against NS1 (Yeung et al., 1991) were
a generous gift from P. Tattersall (Yale School of Medicine). Secondary
antibodies for immunoﬂuorescence (IF) microscopy were from Jackson
ImmunoResearch Laboratories. The polyclonal rabbit Gal-3 antibody
(H-160) was from Santa Cruz Biotechnology. The monoclonal mouse
antibody (AC-15) was from Abcam. The Phycoerythrin (PE)-conjugated
secondary antibody for ﬂow cytometry was from IMgenex. L-PHA-HRP
was from EY laboratories.
siRNA
LA9 cells were either mock transfected with Lipofectamine
RNAiMAX (Invitrogen) or transfected with previously described
siRNA oligonucleotide sequences targeting Gal-3 (Henderson et al.,
2006) accordingly to the manufacturer’s recommendations. A pool
Fig. 4. MVMp infectivity is abolished in Mgat5 / cells as shown by Western
blot and plaque assay. (A) LA9, PyMT, Mgat5/ , and Mgat5-rescued (Mgat5-R)
cells were infected with MVMp at an MOI of 8 for 24 h at 37 1C and prepared for
Western blot analysis. The viral protein NS1 and the cellular actin (loading control)
were detected using speciﬁc antibodies. Res: Mgat5-rescued; /: Mgat5/ .
(B) Plaque assays of MVMp in the indicated cells. LA9, PyMT, Mgat5/ , and
Mgat5-rescued cells were mock-infected (Cont) or infected with MVMp at the
dilutions indicated (starting at an MOI of 8) and processed for plaque assay. The
panel showed is representative for two independent experiments.
Fig. 5. MVMp cellular uptake is reduced in Mgat5 / cells. (A) PyMT, Mgat5/ ,
and Mgat5-rescued (Mgat5-R) cells were infected with MVMp at an MOI of 8 for
4 h at 37 1C and prepared for IF microscopy analysis. MVMp (red) was detected
using a speciﬁc antibody and DAPI (blue) was used to observe the nucleus.
(B) Quantiﬁcation of MVMp ﬂuorescence intensity signal as observed by IF
microscopy from three independent experiments performed as described in A.
Bar graphs show the mean7standard error of the mean (n¼100, ** po0.01).
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of four non-targeting siRNAs (ON-TARGETplus Non-Targeting Pool,
Dharmacon) was used as control siRNA. Expression of Gal-3 was
assessed by Western blot and immunoﬂuorescence microscopy
24 h after transfection.
MVMp uptake analysis
Cells grown as monolayers at about 50% conﬂuence were incu-
bated with infection medium (IM: DMEM containing 1% glutamine)
containing 100 nM baﬁlomycin A1 (bafA1) for 1 h at 37 1C, and then
with MVMp (MOI of 4 or 8) for 15 min at 4 1C in IM. The virus-
containing medium was then replaced with IM containing 100 nM
BFLA1, and the cells were incubated for 2 h or 4 h at 37 1C and 5%
CO2, before preparation for IF microscopy. MVMp was detected with
a speciﬁc anti-capsid antibody.
MVMp infection analysis
Cells grown as monolayers at about 50% conﬂuence were
incubated with MVMp (MOI of 2, 4 or 8) for 15 min at 4 1C in
IM. The virus-containing mediumwas then replaced with fresh IM,
the cells were incubated for 24 h at 37 1C and prepared for IF
microscopy or Western blot analysis. MVMp and the viral NS1
protein were detected using speciﬁc antibodies.
Immunoﬂuorescence (IF) microscopy
Cells grown on glass coverslips and assayed as indicated above
were rinsed once with PBS, ﬁxed with 4% paraformaldehyde (PFA)
in water for 10 min at 4 1C, permeabilized with 0.2% Triton X-100
in PBS containing 2.5% BSA for 2 min at room temperature (RT),
and blocked with PBS containing 2.5% BSA for 30 min at RT. Cells
were incubated with primary antibodies for 1 h at RT, washed with
PBS containing 2.5% BSA, and then incubated with ﬂuorescently-
labeled secondary antibodies for 20 min at RT. Cells were rinsed
several times with PBS containing 2.5% BSA and mounted in
Prolong Gold Antifade with DAPI.
Confocal microscopy and image analysis
All IF microscopy images shown here were acquired using a
Fluoview 1000 confocal laser-scanning microscope (Olympus). Larger
scale images were obtained with a 60plan apochromatic (pinhole
150 mm), and the single cell images with a 100plan apochromatic
Fig. 6. MVMp binding to the cell surface is not affected in Mgat5 / cells. Cells grown on plastic dishes were incubated with MVMp at an MOI of 8 for 15 min at 4 1C,
washed with PBS, trypsinized, ﬁxed, and subjected to FACS analysis. MVMp was detected using a speciﬁc anti-capsid antibody. As controls of the antibodies speciﬁcity, the
cells were mock incubated with buffer in the absence of any antibody (Auto-ﬂuorescence) or incubation with the primary antibody was omitted (No primary ab). The ﬁgure
on the bottom right shows the quantiﬁcation of the shift of the red binding curve compared to the control curve (yellow no primary antibody curve). Bar graphs show
mean7standard error of the mean (n¼30,000) from three independent experiments. ns: not signiﬁcant.
Fig. 7. Gal-3 expression proﬁle in various cancer cells. Total cell lysates of human
thyroid (Shankar et al., 2012), prostate (Pacis et al., 2000), and breast (Sathisha
et al., 2007) cancer cells were prepared for Western blot analysis. Gal-3 and the
cellular actin (loading control) were detected using speciﬁc antibodies.
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(pinhole 185 mm). All the ﬂuorescence images shown are represen-
tative for at least three independent experiments, and values are
given as mean of triplicates7standard deviation (SD). Statistical
signiﬁcance was determined by unpaired Student’s t test.
Western blot
Cells were washed with ice-cold PBS, scraped, and resuspended in
lysis buffer (20 mM Tris–HCl, pH 7.6, 0.5% NP-40, 250 mM NaCl,
3 mM EDTA, 3 mM EGTA containing freshly added 2 mM DTT,
0.5 mM PMSF, 1 mM sodium vanadate, 2.5 mM sodium ﬂuoride,
and 1 μM leupeptin) for 30 min at 4 1C. 10 mg total cell lysates were
run through a 10% SDS-PAGE and transferred to nitrocellulose
membrane. Membranes were blocked with PBS containing 0.1%
Tween-20 and 5% skim milk followed by overnight incubation with
primary antibodies diluted in PBS containing 0.5% Tween 20 and
0.25% skim milk. After several washes, primary antibodies were
detected using HRP-conjugated secondary antibodies. For loading
control, membranes were stripped with stripping buffer (1.5% SDS,
1% β-mercaptoethanol, 0.6% Tris base in H2O) and re-probed for
loading control with Actin primary antibodies as described above. All
the Western blots showed are representative for at least 2 indepen-
dent experiments.
Plaque assay
Cells were grown to about 30% conﬂuence in 6-cm plastic dishes,
washed with PBS, and incubated with MVMp (1 in 10 dilution,
starting at a MOI of 8) in Dilution medium (DMEM containing 1% FBS,
10 mM Hepes) for 1 h at 37 1C. After removal of the virus, 7 ml of
Overlay medium (MEM containing 5% FBS, 1% tryptose phosphate,
0.75% low melting point agarose, and 100 mg/ml Gentamycin) were
added to each plate and allowed to solidify at RT for 15 min. The cells
were then grown for 4 days at 37 1C and 5% CO2. After this incubation
time, cells were ﬁxed in 10% formaldehyde for 30 min, washed with
water, and stained with 0.3% methylene blue for 30 min.
Flow cytometry
Cells grown on tissue culture dishes as monolayers at about 60%
conﬂuence were incubated with MVMp (MOI of 8) for 15 min at 4 1C.
After a wash in ice cold PBS, the cells were detached from the dishes
by incubating them with trypsin-EDTA for 30 min at 4 1C. Next, cells
were ﬁxed with 2% PFA in water for 15 min at 4 1C and blocked with
PBS containing 2.5% BSA for 20 min at 4 1C. Cells were then incubated
with MVMp anti-capsid antibody (dilution 1/200) for 30 min at 4 1C,
washed with PBS containing 2.5% BSA, and incubated with PE-
conjugated secondary antibody (dilution 1/500) for 30 min at 4 1C.
After several washes in PBS containing 2.5% BSA, the cells were
analyzed with a FACS LSRII ﬂow cytometer (BD Biosciences).
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